SEC Form 4
Ultragenyx Pharmaceutical Inc. (RARE) insider trading
In the 12 months to Oct 26, 2026, 9 RARE insiders reported open-market sales of $3.8M across 25 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $3.8M
- 25 filings · 9 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 13 of 25
- $1.3M of $3.8M sold (35%)
Who traded RARE, and when
- Sale
- Sale, pre-arranged (10b5-1)
RARE daily close from Oct 27, 2025 to Oct 26, 2026, between $12.88 and $36.54, last $16.08. 25 sale and 0 purchase filings by 9 insiders, marked at their filing dates. Emil D. Kakkis, President & CEO: sold $1.2M across 1 filing, first filed Mar 3, 2026, last Mar 3, 2026. Howard Horn, Chief Financial Officer: sold $1.2M across 10 filings, first filed Dec 11, 2025, last Oct 19, 2026. Karah Herdman Parschauer, EVP and Chief Legal Officer: sold $487.9K across 4 filings, first filed Mar 3, 2026, last Aug 4, 2026. Erik Harris, EVP & Chief Commercial Officer: sold $240.3K across 1 filing, first filed Mar 3, 2026, last Mar 3, 2026. John Richard Pinion, Officer (see filing): sold $228.7K across 1 filing, first filed Mar 3, 2026, last Mar 3, 2026. Eric Crombez, EVP and Chief Medical Officer: sold $168.8K across 2 filings, first filed Mar 3, 2026, last May 6, 2026. 3 others: sold $254.1K across 6 filings, first filed Dec 30, 2025, last Sep 15, 2026.
Largest mark · tap a row for others
Emil D. Kakkis · President & CEO
Sale $1,240,411
54,404 shares at $22.80 avg
Filed Mar 3, 2026 · traded Mar 2
Close on filing date $22.07
Emil D. Kakkis · President & CEO
President & CEO
$1.2M soldHoward Horn · Chief Financial Officer
Chief Financial Officer
$1.2M soldKarah Herdman Parschauer · EVP and Chief Legal Officer
EVP and Chief Legal Officer
$487.9K soldErik Harris · EVP & Chief Commercial Officer
EVP & Chief Commercial Officer
$240.3K soldJohn Richard Pinion · Officer (see filing)
Officer (see filing)
$228.7K soldEric Crombez · EVP and Chief Medical Officer
EVP and Chief Medical Officer
$168.8K sold3 others
Combined, one mark per week
$254.1K soldOpen-market trades
25 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Emil D. Kakkis | President & CEO | $1.2M | — | 1 | — | |
| Howard Horn | Chief Financial Officer | $1.2M | — | 10 | 91% of sales | |
| Karah Herdman Parschauer | EVP and Chief Legal Officer | $487.9K | — | 4 | 19% of sales | |
| Erik Harris | EVP & Chief Commercial Officer | $240.3K | — | 1 | — | |
| John Richard Pinion | Officer (see filing) | $228.7K | — | 1 | — | |
| Eric Crombez | EVP and Chief Medical Officer | $168.8K | — | 2 | — | |
| Shehnaaz Suliman | Director | $144.2K | — | 1 | 100% of sales | |
| Theodore Alan Huizenga | SVP, Chief Accounting Officer | $59.8K | — | 4 | 29% of sales | |
| Corazon (Corsee) D. Sanders | Director | $50.1K | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Howard Horn Chief Financial Officer | Sale | 7,066 | $15.27 | $107.9K | 89,229 | |
traded | Theodore Alan Huizenga SVP, Chief Accounting Officer | SalePre-arranged (10b5-1) | 1,283 | $13.57 | $17.4K | 67,863 | |
traded | Theodore Alan Huizenga SVP, Chief Accounting Officer | Sale | 161 | $13.99 | $2.3K | 69,146 | |
traded | Howard Horn Chief Financial Officer | SalePre-arranged (10b5-1) | 4,696 | $24.92 | $117.0K | 96,295 | |
traded | Karah Herdman Parschauer EVP and Chief Legal Officer | SalePre-arranged (10b5-1) | 1,900 | $24.92 | $47.3K | 92,562 | |
traded | Howard Horn Chief Financial Officer | SalePre-arranged (10b5-1) | 4,698 | $33.13 | $155.6K | 100,991 | |
traded | Karah Herdman Parschauer EVP and Chief Legal Officer | SalePre-arranged (10b5-1) | 1,899 | $24.62 | $46.8K | 94,462 | |
traded | Corazon (Corsee) D. Sanders Director | Sale | 2,000 | $25.05 | $50.1K | 21,095 | |
traded | Howard Horn Chief Financial Officer | SalePre-arranged (10b5-1) | 4,653 | $23.77 | $110.6K | 105,689 | |
traded | Shehnaaz Suliman Director | SalePre-arranged (10b5-1) | 5,740 | $25.12 | $144.2K | 27,951 | |
traded | Eric Crombez EVP and Chief Medical Officer | Sale | 344 | $24.96 | $8.6K | 111,189 | |
traded | Howard Horn Chief Financial Officer | SalePre-arranged (10b5-1) | 4,683 | $24.90 | $116.6K | 110,342 | |
traded | Howard Horn Chief Financial Officer | SalePre-arranged (10b5-1) | 4,683 | $20.97 | $98.2K | 80,351 | |
traded | Karah Herdman Parschauer EVP and Chief Legal Officer | Sale | 9,526 | $21.87 | $208.3K | 66,820 | |
traded | Eric Crombez EVP and Chief Medical Officer | Sale | 7,029 | $22.80 | $160.3K | 76,301 | |
traded | Howard Horn Chief Financial Officer | SalePre-arranged (10b5-1) | 10,044 | $22.65 | $227.5K | 85,034 | |
traded | Theodore Alan Huizenga SVP, Chief Accounting Officer | Sale | 1,632 | $22.80 | $37.2K | 48,670 | |
traded | Karah Herdman Parschauer EVP and Chief Legal Officer | Sale | 8,135 | $22.80 | $185.5K | 76,346 | |
traded | Emil D. Kakkis President & CEO | Sale | 54,404 | $22.80 | $1.2M | 658,994 | |
traded | Erik Harris EVP & Chief Commercial Officer | Sale | 10,539 | $22.80 | $240.3K | 89,515 | |
traded | John Richard Pinion Officer (see filing) | Sale | 10,029 | $22.80 | $228.7K | 110,026 | |
traded | Howard Horn Chief Financial Officer | SalePre-arranged (10b5-1) | 3,061 | $23.56 | $72.1K | 88,935 | |
traded | Howard Horn Chief Financial Officer | SalePre-arranged (10b5-1) | 3,150 | $22.84 | $71.9K | 91,996 | |
traded | Theodore Alan Huizenga SVP, Chief Accounting Officer | Sale | 85 | $34.38 | $2.9K | 50,450 | |
traded | Howard Horn Chief Financial Officer | SalePre-arranged (10b5-1) | 3,081 | $36.38 | $112.1K | 95,146 |
GET /stocks/filings/vX/form-4?tickers=RARE&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"RARE"
],
"issuer_cik": "0001515673",
"owner_cik": "0001786335",
"accession_number": "0001193125-26-425032",
"form_type": "4",
"filing_date": "2026-10-19",
"period_of_report": "2026-10-15",
"issuer_name": "Ultragenyx Pharmaceutical Inc.",
"issuer_trading_symbol": "RARE",
"owner_name": "Horn Howard",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Financial Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-10-15",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 7066,
"transaction_price_per_share": 15.27,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 89229,
"transaction_value": 107897.81999999999,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Represents shares sold to pay required tax withholdings due to the vesting of RSUs."
},
{
"id": "F2",
"description": "Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."
}
]
},
{
"tickers": [
"RARE"
],
"issuer_cik": "0001515673",
"owner_cik": "0001603347",
"accession_number": "0001193125-26-392233",
"form_type": "4",
"filing_date": "2026-09-15",
"period_of_report": "2026-09-15",
"issuer_name": "Ultragenyx Pharmaceutical Inc.",
"issuer_trading_symbol": "RARE",
"owner_name": "Huizenga Theodore Alan",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "SVP, Chief Accounting Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-15",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 1283,
"transaction_price_per_share": 13.57,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 67863,
"transaction_value": 17410.31,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 24 records
- Tax withholding2 records
- Grants and awards22 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Ultragenyx Pharmaceutical Inc.'s CEO sold stock?
Yes. Emil D. Kakkis (CEO) sold 54,404 shares ($1.2M) in Mar 2026.
How current is RARE’s insider data?
These are RARE Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track RARE insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for RARE every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.